Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C DeWolf

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
The Journal of Urology|July 21, 2010
Re: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Editorial commentWilliam C Dewolf
European Urology|May 13, 2008
Re: are doctors examining prostates in university hospital?William C Dewolf
Urology|April 29, 2014
Editorial commentWilliam C DeWolf
Stem Cells (Dayton, Ohio)|November 25, 2006
The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinomaWilliam M Schopperle, William C DeWolf
The Journal of Urology|March 17, 2004
The cell cycle and its relevance to the urologistWilliam C DeWolf, Sandra M Gaston
The Journal of Urology|March 26, 2002
Does the outpatient setting provide the best environment for medical student learning of urology?B Price Kerfoot, William C DeWolf
Urologic Oncology|March 17, 2009
The hybrid of basic science and clinical training for the urologic oncologist: Necessity or waste?Aria F Olumi, William C Dewolf
The Journal of Urology|June 7, 2002
Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenomaJeong H Yoon, William C Dewolf
Neurourology and Urodynamics|November 9, 2018
Expectant long-term follow-up of patients with chronic urinary retentionAlejandro Abello, William C DeWolf, Anurag K Das
Biochemical and Biophysical Research Communications|July 6, 2010
The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cellsWilliam M Schopperle, Jung M Lee, William C Dewolf
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Urology|July 21, 2010
Re: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Editorial commentWilliam C Dewolf
European Urology|May 13, 2008
Re: are doctors examining prostates in university hospital?William C Dewolf
Urology|April 29, 2014
Editorial commentWilliam C DeWolf
Stem Cells (Dayton, Ohio)|November 25, 2006
The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinomaWilliam M Schopperle, William C DeWolf
The Journal of Urology|March 17, 2004
The cell cycle and its relevance to the urologistWilliam C DeWolf, Sandra M Gaston
The Journal of Urology|March 26, 2002
Does the outpatient setting provide the best environment for medical student learning of urology?B Price Kerfoot, William C DeWolf
Urologic Oncology|March 17, 2009
The hybrid of basic science and clinical training for the urologic oncologist: Necessity or waste?Aria F Olumi, William C Dewolf
The Journal of Urology|June 7, 2002
Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenomaJeong H Yoon, William C Dewolf
Neurourology and Urodynamics|November 9, 2018
Expectant long-term follow-up of patients with chronic urinary retentionAlejandro Abello, William C DeWolf, Anurag K Das
Biochemical and Biophysical Research Communications|July 6, 2010
The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cellsWilliam M Schopperle, Jung M Lee, William C Dewolf
Pageof 5